Trade Compugen Ltd. - Ordinary Shares - CGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0296 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.4352 |
| Open | 1.4352 |
| 1-Year Change | -44.1% |
| Day's Range | 1.3852 - 1.4452 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 1.4352 | -0.0600 | -4.01% | 1.4952 | 1.4952 | 1.3952 |
| Mar 28, 2025 | 1.5252 | 0.0200 | 1.33% | 1.5052 | 1.5252 | 1.5052 |
| Mar 27, 2025 | 1.5152 | -0.0100 | -0.66% | 1.5252 | 1.5452 | 1.5152 |
| Mar 26, 2025 | 1.5252 | -0.0100 | -0.65% | 1.5352 | 1.5452 | 1.4752 |
| Mar 25, 2025 | 1.5552 | -0.0700 | -4.31% | 1.6252 | 1.6252 | 1.5452 |
| Mar 24, 2025 | 1.6052 | 0.0300 | 1.90% | 1.5752 | 1.6052 | 1.5752 |
| Mar 21, 2025 | 1.5652 | 0.0100 | 0.64% | 1.5552 | 1.5852 | 1.5452 |
| Mar 20, 2025 | 1.5852 | 0.0500 | 3.26% | 1.5352 | 1.6252 | 1.5352 |
| Mar 19, 2025 | 1.5752 | 0.0300 | 1.94% | 1.5452 | 1.5852 | 1.5352 |
| Mar 18, 2025 | 1.5552 | -0.0600 | -3.71% | 1.6152 | 1.6152 | 1.5452 |
| Mar 17, 2025 | 1.6152 | 0.0000 | 0.00% | 1.6152 | 1.6352 | 1.5852 |
| Mar 14, 2025 | 1.6452 | 0.0500 | 3.13% | 1.5952 | 1.6652 | 1.5952 |
| Mar 13, 2025 | 1.6052 | -0.0400 | -2.43% | 1.6452 | 1.6752 | 1.5952 |
| Mar 12, 2025 | 1.6852 | 0.0600 | 3.69% | 1.6252 | 1.7252 | 1.6252 |
| Mar 11, 2025 | 1.6152 | 0.0500 | 3.19% | 1.5652 | 1.6452 | 1.5552 |
| Mar 10, 2025 | 1.5752 | -0.0300 | -1.87% | 1.6052 | 1.6352 | 1.5252 |
| Mar 7, 2025 | 1.6352 | -0.0400 | -2.39% | 1.6752 | 1.6752 | 1.5852 |
| Mar 6, 2025 | 1.6652 | -0.0900 | -5.13% | 1.7552 | 1.7852 | 1.6552 |
| Mar 5, 2025 | 1.7952 | 0.1000 | 5.90% | 1.6952 | 1.7952 | 1.6952 |
| Mar 4, 2025 | 1.7052 | -0.0600 | -3.40% | 1.7652 | 1.7852 | 1.6752 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Compugen Ltd. Company profile
About Compugen Ltd. (USA)
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Compugen Ltd. (USA) revenues increased from $2M to $6M. Net loss increased 15% to $34.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 24% to $26.7M (expense), Interest Income decrease of 49% to $894K (income).
Equity composition
Ordinary Shares NIS.01 Par, 12/10 50M auth., 33,915,545 issd. Insiders own 11.33%. IPO: 8/11/00, 5M shares @ $10 by FleetBoston Robertson Stephens. FY'00 financials are reclassified.
| Industry: | Biotechnology & Medical Research (NEC) |
26 הרוקמים
HOLON
5885849
IL
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com